Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
AIM: To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D). RESULTS: Nine RCTs (N = 2292; most with low risk of bias) were included.
AIM: To assess the effects of mazdutide on body weight, HbA1c, metabolic outcomes, and adverse events in adults with overweight/obesity and/or type 2 diabetes (T2D). RESULTS: Nine RCTs (N = 2292; most with low risk of bias) were included.
What the study was
- Study design
- Meta-analysis
- Sample size
- 2292
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Diabetes, obesity & metabolism
Why it surfaced
High-priority Hematologic malignancies study: promising preliminary signal warrants immediate pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.